Search Results
Results found for "Structure Therapeutics"
- Fluorescent Ligands Targeting Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2
Here, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
his interview, Regulators of G protein Signaling (RGS proteins) might hold some of the most untapped therapeutic
- Odorant receptors – a bit of smell for drug discovery
Selective screening assays for ectopic ORs as well as investment on the structural characterization of function of ORs in vivo, development of in vitro systems for functional assays and the availability of structural information for structure-based drug design.
- Novo Nordisk moves to strengthen obesity efforts
Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics
- Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs
In this review, we discuss the relationship between structure, function, and dynamics of opioid receptors
- Functional modulation of PTH1R activation and signaling by RAMP2
Employing homology modeling, we describe the putative structural molecular basis underlying our functional
- A broad look into the future of systemic sclerosis
The authors provide a hierarchical structure into the studies of the pathogenesis of SSc starting with
- Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast
Pina Cardarelli, CSO of GPCR Therapeutics.
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
It’s about revealing therapeutic liabilities before they derail development. constitutive activity play in uncovering inverse agonists , and how can you exploit this phenomenon for novel therapeutic
- Targeting the M1 muscarinic receptor in neurodegenerative disease
the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic
- Mechanistic Understanding of the Palmitoylation of Go Protein in the Allosteric Regulation of...
Structural and energetic analyses indicated that the palmitoylation of Go can allosterically stabilize
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic
- Dr. Juan José Fung - Dr. GPCR Podcast
Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- New Resources in GPCRdb
present and demonstrate the newest resources of the GPCRdb: 1) the new G protein resources and 2) the structural
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
hydrophobic groups of different sizes on both sides of the five-membered ring scaffold guided by the crystal structure
- Lysine 101 in the CRAC Motif in Transmembrane Helix 2 Confers Cholesterol-Induced Thermal...
We envision that our results could have potential implications in structural biological advancements
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
PVT NPSR1 neurons recruit the nucleus accumbens shell and structures in the prefrontal cortex and amygdala
- Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild trauma
This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
– CXCR4 oligomer disruption boosts therapeutic response in lymphoid neoplasms Dr.
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental...
of membrane proteins in eukaryotes and the largest drug target family to date, exhibit diversity in structure
- 📰 GPCR Weekly News, January 15 to 21, 2024
procerum Editorial: Advanced biophysical and biochemical technologies to study GPCR signal transduction Structural Clinical Pharmacology 2026 GPCR Jobs NEW Post-Doc position NEW Lead Researcher Senior Researcher in Structural
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- TeachOpenCADD - A teaching platform for computer-aided drug design
Open source programming packages for cheminformatics and structural bioinformatics are powerful tools
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)






